SCHEMBL6901515

SCHEMBL6901515

CCc1cc2c(Cl)nc(C3CCC(CC(=O)OC)CC3)nc2s1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TMIGD3 P0DMS9 1/20 0.45
ADORA1 P30542 1/20 0.45
SELE P16581 1/20 0.38
VCAM1 P19320 1/20 0.38
ALDH1A1 P00352 6/20 0.38
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
KDM4E B2RXH2 3/20 0.35
HSD17B10 Q99714 1/20 0.35
PDE10A Q9Y233 3/20 0.35
DGAT1 O75907 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
P2RY12 Q9H244 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6901517 0.80 TMIGD3 (0.41) TMIGD3ADORA1SELEVCAM1ALDH1A1
SCHEMBL6905704 0.79 PDE5A (0.40)
SCHEMBL6763192 0.76 TSHR (0.44) ALDH1A1TSHRMAPK1KDM4EHSD17B10
SCHEMBL7656292 0.72 NPC1 (0.53) ALDH1A1TSHRMAPK1KDM4EHSD17B10
SCHEMBL6706659 0.72 PDE5A (0.40) ALDH1A1KDM4EHSD17B10
SCHEMBL6706646 0.72 SELE (0.44) TMIGD3ADORA1SELEVCAM1ALDH1A1
SCHEMBL1966694 0.71 SELE (0.48) TMIGD3ADORA1SELEVCAM1ALDH1A1
SCHEMBL6706662 0.70 SELE (0.42) TMIGD3ADORA1SELEVCAM1ALDH1A1
SCHEMBL6708399 0.70 SELE (0.41) TMIGD3ADORA1SELEVCAM1ALDH1A1
SCHEMBL6708349 0.69 HPGD (0.41) TMIGD3ADORA1SELEVCAM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040077664-A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates MERCK PATENT GMBH (DE) 2004-04-22 US disclosed
US-20040072846-A1 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives MERCK PATENT GMBH (DE) 2004-04-15 US disclosed
US-6495554-B2 PHOSPHODIESTERASE V INHIBITORS, TREATING CARDIOVASCULAR DISORDERS, AND THERAPY OF ERECTILE DYSFUNCTION. MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2002-12-17 US disclosed
US-20020132818-A1 Thienopyrimidines MERCK PATENT GMBH (DE) 2002-09-19 US disclosed
US-6420368-B1 DISEASES OF THE CARDIOVASCULAR SYSTEM AND FOR TREATMENT AND/OR THERAPY OF ERECTILE DYSFUNCTION. MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2002-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077664-A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates PTGIS, DPYD, PTGIR TMIGD3 3660/4885ADORA1 290/4885SELE 4109/4885
US-20020132818-A1 Thienopyrimidines PDE5A, PDE3B, PDE3A TMIGD3 3124/4885ADORA1 756/4885SELE 1533/4885
US-20040072846-A1 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives PTGER1, TBXA2R, PTGIS TMIGD3 3111/4885ADORA1 270/4885SELE 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.